Part of grupo corporativo landon sl
Clinical Trials
51
37 active
Approvals
134
Total approvals
Agencies
3
Regulatory bodies
Founded
1943
Active, not recruiting
37
72.5%
Completed
1
2.0%
Recruiting
13
25.5%
- Evotec and Almirall successfully nominated their first preclinical development candidate for immune-mediated inflammatory skin diseases within just two years, significantly outperforming standard industry timelines. - The collaboration leverages Evotec's AI/ML-enhanced discovery platforms combined with Almirall's dermatology expertise to address high unmet medical needs in severe skin diseases. - The partnership includes potential milestone payments of up to €230 million per program and high single-digit royalties, with the program now advancing toward IND submission through Evotec's INDiGO platform.
- Almirall S.A. recently completed a Phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of LAD603 in healthy adult subjects. - The company has now initiated a Phase 2 randomized, placebo-controlled, double-blind trial to evaluate LAD603's efficacy and safety in adults with severe to very severe alopecia areata. - The Phase 2 study tests three dose levels of the subcutaneous injectable drug against placebo over 28 weeks, aiming to find the optimal balance of hair regrowth and safety. - This advancement expands Almirall's dermatology pipeline into alopecia areata, a condition with limited treatment options and high emotional impact for patients.
- The FDA has approved Ebglyss (lebrikizumab-lbkz) for adults and children 12+ with moderate-to-severe atopic dermatitis not controlled by topical treatments. - Clinical trials showed significant skin clearance as early as four weeks and itch relief as early as two weeks with Ebglyss treatment. - Ebglyss offers long-lasting efficacy, with many patients maintaining results for one year with a monthly maintenance dose. - Ebglyss, a targeted IL-13 inhibitor, provides a new first-line biologic option for those whose eczema is not adequately managed by topicals.
- The FDA has approved Ebglyss (lebrikizumab) for adults and children 12 years and older with moderate-to-severe atopic dermatitis not well controlled by topical treatments. - Clinical trials showed Ebglyss significantly cleared skin in patients as early as four weeks and provided meaningful itch relief as early as two weeks. - Ebglyss offers long-lasting efficacy with a monthly maintenance dose after an initial treatment phase, providing sustained relief for up to one year. - Ebglyss, a targeted IL-13 inhibitor, can be used with or without topical corticosteroids, offering a new first-line biologic treatment option.
